257 results on '"Veltri, Enrico"'
Search Results
2. Pooled Analyses of Effects on C-Reactive Protein and Low Density Lipoprotein Cholesterol in Placebo-Controlled Trials of Ezetimibe Monotherapy or Ezetimibe Added to Baseline Statin Therapy
3. Efficacy and Safety of Coadministration of Ezetimibe and Simvastatin in Adolescents With Heterozygous Familial Hypercholesterolemia
4. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: Results from two open-label extension studies in hypercholesterolemic patients
5. Early versus delayed, provisional eptifibatide in acute coronary syndromes
6. Simvastatin with or without Ezetimibe in familial Hypercholesterolemia
7. Comparison of Effects of Ezetimibe/Simvastatin Versus Simvastatin Versus Atorvastatin in Reducing C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels
8. Efficacy and Safety of Coadministration of Ezetimibe and Statins in Elderly Patients with Primary Hypercholesterolaemia
9. Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: Application to Germany, Spain and Norway
10. Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia: design and rationale of the Ezetimibi and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial
11. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered wtih atorvastatin
12. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: A post Hoc analysis of subpopulations from three pooled clinical trials
13. Projected coronary heart disease risk benefit with ezetimibe
14. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients
15. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes
16. Efficacy and safety of ezetimibe and ezetimibe plus statin therapy in patients aged under 65, 65–74 and 75 years and older
17. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction
18. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin
19. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50 trial
20. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia
21. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies
22. The automatic implantable cardioverter-defrillator: long-term clinical experience and outcome at a hospital without an open-heart surgery program
23. Prevention of arrhythmic death with the automatic implantable cardioverter-defibrillator
24. Automatic Implantable Defibrillator: Six-Year Clinical Experience
25. Efficacy and safety of coadministration of ezetimibe and simvastatin in African-American patients with primary hypercholesterolemia
26. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA.CER) trial : study design and rationale
27. Early versus delayed, provisional eptifibatide in acute coronary syndromes.
- Abstract
Background Glycoprotein IIb/IIIa inhibitors are indicated in patients with acute coronary syndromes who are undergoing an invasive procedure. The optimal timing of the initiation of such therapy is unknown. Methods We compared a strategy of early, routine administration of eptifibatide with delayed, provisional administration in 9492 patients who had acute coronary syndromes without ST-segment elevation and who were assigned to an invasive strategy. Patients were randomly assigned to receive either early eptifibatide (two boluses, each containing 180 µg per kilogram of body weight, administered 10 minutes apart, and a standard infusion
![]("http://content.nejm.org/math/ge.gif")
12 hours before angiography) or a matching placebo infusion with provisional use of eptifibatide after angiography (delayed eptifibatide). The primary efficacy end point was a composite of death, myocardial infarction, recurrent ischemia requiring urgent revascularization, or the occurrence of a thrombotic complication during percutaneous coronary intervention that required bolus therapy opposite to the initial study-group assignment ("thrombotic bailout") at 96 hours. The key secondary end point was a composite of death or myocardial infarction within the first 30 days. Key safety end points were bleeding and the need for transfusion within the first 120 hours after randomization. Results The primary end point occurred in 9.3% of patients in the early-eptifibatide group and in 10.0% in the delayed-eptifibatide group (odds ratio, 0.92; 95% confidence interval [CI], 0.80 to 1.06; P=0.23). At 30 days, the rate of death or myocardial infarction was 11.2% in the early-eptifibatide group, as compared with 12.3% in the delayed-eptifibatide group (odds ratio, 0.89; 95% CI, 0.79 to 1.01; P=0.08). Patients in the early-eptifibatide group had significantly higher rates of bleeding and red-cell transfusion. There was no significant difference between the two groups in rates of severe bleeding or n
28. Ventricular tachycardia following ingestion of a commonly used antihistamine
29. Letter by Tershakovec et al Regarding Article, “Evidence for Statin Pleiotropy in Humans: Differential Effects of Statins and Ezetimibe on Rho-Associated Coiled-Coil Containing Protein Kinase Activity, Endothelial Function, and Inflammation”
30. Long-term safety and tolerability of ezetimibe coadministered with simvastatin in hypercholesterolemic patients: a randomized, 12-month double-blind extension study
31. Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe–statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia
32. Abstract 3010: Thrombin Receptor Antagonist (TRA;SCH530348) is a Selective, Potent Inhibitor of PAR1 Activity with Predictable Pharmacokinetics
33. Efficacy and Safety of Ezetimibe/Simvastatin Versus Simvastatin Monotherapy in Hypercholesterolemic Patients with Metabolic Syndrome
34. Zetia: Inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to Reduce Intestinal Cholesterol Absorption and Treat Hyperlipidemia
35. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis
36. Consistency in Efficacy and Safety of Ezetimibe Coadministered with Statins for Treatment of Hypercholesterolemia in Women and Men
37. Pharmacodynamic and pharmaco-kinetic interaction between fenofibrate and ezetimibe*
38. Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin
39. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein
40. Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary Hypercholesterolemia
41. Ezetimibe coadministered with low dose statins in primary hypercholesterolemia: Lipid profiles comparable to high-dose statin monotherapy
42. C-reactive protein is reduced during ezetimibe coadministration with simvastatin in patients with primary hypercholesterolemia
43. Ezetimibe coadministered with atorvastatin compared to atorvastatin alone in the attainment of low-density lipoprotein goals among high-risk patients with hypercholesterolemia
44. Heterozygous familial hypercholesterolemia: Coadministration of ezetimibe plus atorvastatin
45. Coadministration of ezetimibe with simvastatin
46. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia
47. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia
48. Does cholesterol and/or fat intake affect plasma lipid efficacy of ezetimibe?
49. Ezetimibe co-administered with atorvastatin in 628 patients with primary hypercholesterolemia
50. Ezetimibe significantly reduces low-density lipoprotein cholesterol in homozygous familial hypercholesterolemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.